Tag Archives: TB
Industry Optimism for Advancing TB Research
Scientists optimistic new combination regimens will improve TB treatment and reduce drug resistance, writes Jill Wechsler, Pharm Exec’s Washington Editor.
In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains. Each year, nearly 9 [...]
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D Also tagged AIDS, Developing country, funding, HIV, Médicins Sans Frontières, neglected diseases, TB Alliance, Tuberculosis, WHA, World Health Assembly Leave a comment

TB: A Faster Pace in Progress Against the Wasting Disease